A phase I study to explore the activity and safety of SCH532706, a small molecular chemokine receptor-5 antagonist in HIV type-1-infected patients

Antiviral Therapy

Volumn 14, Issue 1, 2009, Pages 111-115

  Pett, Sarah L ^a,b   McCarthy, Michael C ^c   Cooper, David A ^a,b   MacRae, Karen ^a   Tendolkar, Amol ^c   Norris, Richard ^a   Strizki, Julie M ^c   Williams, Kenneth M ^a,d   Emery, Sean ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; RITONAVIR; SCH 532706; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CD4+ T LYMPHOCYTE; CHEMICAL ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTROCARDIOGRAM; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; INTESTINAL DYSMOTILITY; LABORATORY TEST; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PERICARDITIS; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; QT INTERVAL; RNA VIRUS; SIDE EFFECT; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VIRUS ISOLATION;

ABDOMINAL PAIN; ADMINISTRATION, ORAL; ADULT; CD4 LYMPHOCYTE COUNT; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PERICARDITIS; RECEPTORS, CCR5; RITONAVIR; VIRAL LOAD;

EID: 61849179239     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185:621-628.
2. Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11:1170-1172.
3. Selzentry (maraviroc). Prescribing information. (Updated 7 August 2007. Accessed 1 September 2008.) Available from http://www.fda.gov/cder/ foiAabel/2007/022128lbl.pdf
4. Schürmann D, Fätkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21:1293-1299.
5. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 2007; 196:304-312.
6. Norvir (ritonavir). Product monograph July 2007. Abbott Laboratories, North Chicago, IL, USA.
7. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0. (Updated 4 March 2008. Accessed 1 September 2008.) Available from http://ctep.cancer.gov/ protocolDevelopmentlefectronic_applications/docs/ctcaev3.pdf
8. Boxenbaum H, Battle M. Effective half-life in clinical Pharmacology. J Clin Pharmacol 1995; 35:763-766.
9. McFayden L, Jacqmin P, Wade JR, Weatherley B. Maraviroc exposure-efficacy (<50 copies/ml) analysis in HIV-1-infected treatment-naive subjects - ITT Population (MERIT Study). XVII International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Poster TUPE0053.
10. Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc in combination with an optimised antiretroviral regimen for treatment-experienced subjects, the VICTOR-E1 trial. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Poster 3672.